Table 1.
Antibody status, clinical and descriptive characteristics of early RA patients (75% female) at baseline separately shown for the total cohort (n = 120), AAPA-positive (n = 72), AAPA-negative patients, and by number of positive AAPA. Values shown are median (IQR), unless indicated otherwise.
| Antibody | Total | AAPA− | AAPA+ | 1 AAPA | 2 AAPA | 3 AAPA |
|---|---|---|---|---|---|---|
| n | 120 | 48 | 72 | 28 | 32 | 12 |
| Anti-ac-lysine vimentin (%) | 32.5 | – | 54.2 | 7.1 | 78.1 | 100 |
| Anti-ac-lysine.inv vimentin (%) | 35.0 | – | 58.3 | 53.6 | 46.9 | 100 |
| Anti-ac-ornithine vimentin (%) | 39.2 | – | 65.3 | 39.3 | 75.0 | 100 |
| AAPA total (%) | 60.0 | – | 100 | – | – | – |
| Anti-citrullinated vimentin (%) | 44.2 | 8.3 | 68.1 | 39.3 | 81.3 | 100 |
| Anti carbamylated vimentin (%) | 47.5 | 12.5 | 70.8 | 39.3 | 90.6 | 91.7 |
| RF (%) | 53.3 | 31.3 | 68.1 | 42.9 | 84.4 | 83.3 |
| ACPA (%) | 50.0 | 22.9 | 68.1 | 35.7 | 90.6 | 83.3 |
| Age (years) | 55 (42.7–65) | 57 (41.5–65) | 54.1 (44.4–63.5) | 55.5 (42–65) | 53.3 (48.1–61) | 51.1 (42.1–61.8) |
| Duration of disease (years) | 0 (−0.2–0.1) | −0.1 (−0.2–0.1) | 0 (−0.1–0.1) | −0.1 (−0.4–0.1) | 0 (−0.1–0.2) | 0 (0–0.3) |
| Duration of symptoms (years) | 0.7 (0.3–1.9) | 0.7 (0.3–1.4) | 0.9 (0.3–2.1) | 0.7 (0.2–1.3) | 1.1 (0.5–2.7) | 0.8 (0.4–2.1) |
| C-reactive protein (mg/dl) | 0.8 (0.3–1.6) | 0.5 (0.2–1.2) | 1 (0.4–1.7) | 1 (0.5–1.5) | 1.2 (0.5–1.9) | 1 (0.1–1.9) |
| Patient global assessment (mm) | 36 (17–55.5) | 39 (20–54) | 33 (15–56.5) | 29 (15–52) | 40 (14–60) | 46 (17–53) |
| Evaluator global Assessment (mm) | 20 (11–30) | 18 (11–30) | 23 (10.5–31) | 23 (13.5–41.5) | 23 (11.5–29) | 14 (4–30) |
| Pain (visual analogue scale) (mm) | 36.5 (16.3–56.8) | 35 (15–58) | 40 (16.5–56) | 30 (10.5–52) | 40 (16.5–62) | 42 (18–51) |
| Swollen joint count – 28 joints | 3 (2–5) | 3 (2–4) | 4 (2–6) | 4 (2–6) | 4 (2–6) | 3 (2–8) |
| Tender joint count – 28 joints | 3 (1–7) | 4 (1–8) | 2 (1–7) | 2 (0.5–4.5) | 3 (1–6) | 6 (2–17) |
| SDAI | 15.4 (9.1–22.4) | 13.4 (9.3–23.3) | 16.2 (8.4–22) | 13.6 (7.3–23.2) | 16.2 (7.5–21.1) | 18.4 (12.3–26) |
| CDAI | 14.2 (7.7–20.5) | 12.7 (9–22.9) | 15 (7.3–20.5) | 12.6 (4.9–22.3) | 15.3 (7.3–18.7) | 17 (8.9–25.7) |
AAPA, anti-acetylated peptide antibodies; ACPA, anti-citrullinated-peptide antibodies; CDAI, clinical disease activity index; IQR, interquartile range; SDAI, simplified disease activity index.